Shilpa Medicare Limited (SHILPAMED) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Shilpa Medicare Limited stock ₹252, price ₹938, that is 73.2% below the price, quality 50 out of 100. Rating: strongly overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Shilpa Medicare Limited
SHILPAMED · NSEFar too expensive (fair value 73% below the price) and company just short of the bar, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 12, 2026.
How to read this chart
60‑month range ₹114.14 – ₹1,076 · fair‑value band ₹176.29 – ₹327.39 · the ₹938.35 price screens above the ₹251.84 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 12, 2026.
Every Wednesday you see whether Shilpa Medicare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally.
Show moreShow less
The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. It also provides nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate.
In addition, the company offers intermediates; peptides; biopolymers; biologics; contract development and manufacturing services; and formulations, such as tablets, capsules, liquid injections, dry powder injectable products, oral dissolving films, transdermal patches.
Further, it is involved in the manufacture of specialized oncology formulations; and wind power generation activities. The company was formerly known as Shilpa Antibiotics Ltd and changed its name to Shilpa Medicare Limited in February 2003.
Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India.
Stock analysis
Shilpa Medicare Limited (SHILPAMED) currently trades at ₹938.35, while our model-based Fair Value estimate is ₹251.84, 73% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹258.04 per share, and 0 of the 16 models we run sit above the ₹938.35 price.
Bear case: the Asset-Based group reads lowest at ₹64.96, and 16 of the 16 models stay below the price. Data coverage for this calculation is high.
Scenario range: ₹176.29 (bear) to ₹327.39 (bull), the price of ₹938.35 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Shilpa Medicare Limited reported revenue of ₹15.4B in FY2026 versus ₹11.4B in FY2022, a compound +7.8%/yr. Reported net income was ₹2.4B in FY2026, compounding +41.5%/yr from FY2022.
Key figures
Market cap ₹184B (≈ $1.9B) Small · P/E ratio 54.9 · P/S ratio 8.69 · EPS (TTM) ₹17.08 · Dividend yield 0.1% · Net margin 15.8% · Return on equity 12.8% · Return on assets (EBIT) 6.2% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 62 out of 100 (low confidence).
What moves the price
The share trades about 13% below its 52-week high and 252% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −73%, SHILPAMED screens richer than that median.
Fair Value models
All 16 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
SHILPAMED screens overvalued: fair value 73% below the price. Compare with Merck KGaA →
Compare Shilpa Medicare Limited with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Debt-to-equity by industry
- Price/FCF by industry
- PEG screener for stocks with fair value
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $83.82 | $113.53 | +35% | vs SHILPAMED |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.02 | ¥53.04 | +10% | vs SHILPAMED |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,868 | ₹1,983 | +6% | vs SHILPAMED |
| Haleon plc HLN | $9.17 | $8.47 | −8% | vs SHILPAMED |
| Merck KGaA MRK | €149.70 | €108.83 | −27% | vs SHILPAMED |
| Galderma Group GALD | CHF 191.00 | CHF 112.30 | −41% | vs SHILPAMED |
| Takeda Pharmaceutical Company TAK | $21.43 | $11.20 | −48% | vs SHILPAMED |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs SHILPAMED |
| Teva Pharmaceutical Industries Limited TEVA | $44.50 | $20.74 | −53% | vs SHILPAMED |
| Divi's Laboratories Limited DIVISLAB | ₹11,080 | ₹1,567 | −86% | vs SHILPAMED |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Shilpa Medicare Limited (SHILPAMED) overvalued or undervalued?
What is the fair value of SHILPAMED?
What is the quality score of SHILPAMED?
What is the price target for Shilpa Medicare Limited (SHILPAMED)?
What is the Shilpa Medicare Limited stock forecast for 2026?
What is the revenue of Shilpa Medicare Limited (SHILPAMED)?
Does Shilpa Medicare Limited pay a dividend?
How much is the dividend of Shilpa Medicare Limited (SHILPAMED) and when is the ex-dividend date?
What is the intrinsic value of Shilpa Medicare Limited (SHILPAMED)?
Is Shilpa Medicare Limited stock overvalued or undervalued in 2026?
Is fair value the same as the market price of SHILPAMED?
How much is Shilpa Medicare Limited worth?
What do the bullish and bearish scenarios say about SHILPAMED?
What is the P/E ratio of SHILPAMED?
How solid is the balance sheet of Shilpa Medicare Limited (SHILPAMED)?
How far is SHILPAMED from its 52-week high?
Which stocks are comparable to Shilpa Medicare Limited?
Is Shilpa Medicare Limited stock attractive at the current price?
How is the fair value of SHILPAMED calculated?
Is it still worth investing in stocks now?
What is the share price of Shilpa Medicare Limited (SHILPAMED)?
What should I pay attention to with Shilpa Medicare Limited right now?
Where does the earnings growth of Shilpa Medicare Limited (SHILPAMED) come from?
Key figures of Shilpa Medicare Limited
How large is the market capitalisation of Shilpa Medicare Limited (SHILPAMED)?
What is the P/S ratio of Shilpa Medicare Limited (SHILPAMED)?
What are the earnings per share of Shilpa Medicare Limited (SHILPAMED)?
What is the dividend yield of Shilpa Medicare Limited (SHILPAMED)?
What is the net margin of Shilpa Medicare Limited (SHILPAMED)?
What is the return on equity of Shilpa Medicare Limited (SHILPAMED)?
What is the EBIT return on assets of Shilpa Medicare Limited (SHILPAMED)?
What is the operating margin of Shilpa Medicare Limited (SHILPAMED)?
How fast is revenue growing at Shilpa Medicare Limited (SHILPAMED)?
How fast are earnings growing at Shilpa Medicare Limited (SHILPAMED)?
How much free cash flow does Shilpa Medicare Limited (SHILPAMED) generate?
How much net debt does Shilpa Medicare Limited (SHILPAMED) carry?
Watch Shilpa Medicare Limited in the live analysis
One click puts Shilpa Medicare Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.